Venetoclax with anti CD20 monoclonal antibody

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

May '27

ADPTPhase 2$4.5B

Venetoclax with anti CD20 monoclonal antibody Phase 2 Est. Readout

Venetoclax with anti CD20 monoclonal antibody• Chronic Lymphocytic Leukemia (CLL)81

May 2027~Estimated

00%

Competitive Landscape

0 competitors in Chronic Lymphocytic Leukemia (CLL)

Drug Information

Target Indication

Chronic Lymphocytic Leukemia (CLL)

Clinical Trial

Last updated: 10/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ADPT

Adaptive Biotechnologies Corporation

Related Pipeline

Diffuse Large B-Cell Lymphoma (DLBCL)

Mantle Cell Lymphoma

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts